In the quest to advance AAV vector production, the development of automated AAV capsid titer assays represents a significant leap forward in analytical methodologies. By adopting advanced analytical tools, the manufacturing industry can achieve greater reproducibility, improved productivity, and faster time to results.

This webinar will present a case study describing the evaluation of a high-throughput automated analytical immunoassay platform to accelerate and improve the screening of clones and media for higher capsid titers.

The key objective of the study was to assess the ability of an automated immunoassay platform to improve the current practice of accurately estimating capsid titers throughout manufacture and purification.

View the recording to: 

• Discover an automated immunoassay platform designed for rapid and efficient process insights, using minimal sample volumes
• Learn how automated assays can enhance the screening process to identify the best-performing clones and media conditions for higher full capsid production

If you have problems viewing the webinar, please contact maritha.lundin@gyrosproteintech.com